Published in AVAC Report 2011, this graphic was adapted from the paper authored by UNAIDS and others that advocated for a new “investment framework” for the AIDS response. It models changes in incidence and mortality if the world increases its investment in evidence-based AIDS programs–and what will happen if it doesn’t.
Invest Now to Save Lives and Funds
Core Activities for an Effective AIDS Response
Px Wire July-September 2011, Vol. 4, No. 3
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This edition of PxWire includes a feature on the new momentum to end the AIDS epidemic in light of the recent HPTN 052 results; an exploration of the progress in AIDS vaccine research and the need for evolving trial designs to accommodate new trial results such as those from HPTN 052 and iPrEx; and, as always, a centerspread with an updated timeline of biomedical HIV prevention efficacy trials and a world map showing where various strategies are being tested.
PxWire January-March 2011, Vol. 4, No. 1
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue of PxWire takes inventory of the regulatory, trial-planning and scientific agenda-setting steps that are being taken with respect to recent positive trial results. It reviews ongoing and proposed next steps that have been triggered by the Thai prime-boost AIDS vaccine trial, the CAPRISA 004 microbicide trial and the iPrEx trial of once-daily TDF/FTC for pre-exposure prophylaxis.
Px Wire April-June 2010, Vol. 3, No. 2
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue include: next steps in AIDS vaccine trials in the post-Thai vaccine trial (RV144) era; “test and treat” approach for prevention presented at CROI; a preview of AVAC Report 2010; information on the Microbicides 2010 Pre-Conference Advocacy Workshop; new funding for advocacy related to MSM and prevention research; six new clinical trials looking at enhanced prevention strategies.
Px Wire January-March 2010, Vol. 3, No. 1
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue of PxWire include updates on: the results from MDP 301, a trial of the microbicide PRO 2000, which lay to rest its prospect as a viable microbicide; CDC’s newly modified PrEP trial (TDF2 in Botswana), which changed its status as an efficacy trial to a safety and behavioral study; the evolving effort to understand the Thai prime-boost AIDS vaccine results; recent NIH grants that nearly double global spending on rectal microbicides; and a timeline of 2010 trial milestones—what trial results are expected and what new studies are scheduled to commence?
Anticipating the Results of the Phase III AIDS Vaccine Trial in Thailand
A 2009 document discussing the RV144 vaccine trial in advance of efficacy data. It provides background information on the vaccine candidate and trial design, and explores potential scenarios for the results.
Px Wire January-March 2009, Vol. 2, No. 1
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue of PxWire include a report on data from the Step vaccine trial and animal studies of relevance to the proposed HVTN 505 trial of the NIH Vaccine Research Center DNA-Ad5 combination strategy presented at the Keystone Symposium on HIV prevention–an annual meeting focused on basic and preclinical science. This issue also reviews newly launched trials, lays out this year’s upcoming trial milestones, and gives information on ordering the 2009 AVAC report on the prevention research field, to be released in May.
Px Wire October-December 2008, Vol. 1, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights of this year-end issue include: AVAC’s take on the year in prevention research; an update on the proposed AIDS vaccine trial HVTN 505; news on the female condom and microbicide trials.
Px Wire July-September 2008, Vol. 1, No. 3
PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue of PxWire include a discussion of the no-go decision on the proposed PAVE 100 vaccine trial (though the candidate may yet be tested), updates on women’s input into male circumcision for HIV prevention, and AVAC’s take on indelible moments and themes from the International AIDS Conference in Mexico City in August.